Quoin Pharmaceuticals, Ltd. (QNRX) - Dilution Analysis

10-K filing | 63.1M shares outstanding

8-K filing: Quoin Pharmaceuticals Ltd. completed a private placement offering, issuing ordinary shares and pre-funded warrants, along with Series H, I, J, and K warrants, for gross proceeds of approximately $16.6 million. ($33.33M proceeds)

10-Q filing | 20.6M shares outstanding

10-Q filing | 20.6M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 8,948,164 → 447,408

POS AM filing: Quoin Pharmaceuticals Ltd. is offering 8,988,346 Ordinary Shares represented by 8,988,346 ADSs issuable upon the exercise of Warrants. The company intends to use any net proceeds from the exercise of Warrants for cash for general corporate purposes.

10-K filing | 8.9M shares outstanding

8-K filing: Quoin Pharmaceuticals Ltd. completed a public offering of ordinary shares, warrants, and pre-funded warrants for gross proceeds of approximately $6.8 million. ($8.0M proceeds)

S-1/A filing: Quoin Pharmaceuticals Ltd. is offering ADSs, Pre-Funded Warrants to purchase ADSs and Warrants to purchase ADSs.

S-1 filing: Quoin Pharmaceuticals Ltd. is offering ADSs, Pre-Funded Warrants, Series F Warrants and Series G Warrants to purchase ADSs.

8-K filing: Quoin Pharmaceuticals Ltd. held its 2024 Annual General Meeting of Shareholders on December 5, 2024, approving amendments to the Company's Amended and Restated Articles of Association and non-employee directors' compensation program, including an increase to the annual base retainer and a change to the annual option grant, with the Compensation Committee and the Board granting each non-employee director an option to purchase 57,014 ADSs under Quoin's Plan, with an exercise price equal to $0.78 per ADS on December 9, 2029.

10-Q filing | 5.0M shares outstanding

10-Q filing | 4.0M shares outstanding

10-Q filing | 3.8M shares outstanding

POS AM filing: This POS AM filing relates to the registration of Ordinary Shares represented by ADSs issuable upon the exercise of Warrants, with the company intending to use any net proceeds from the exercise of warrants for general corporate purposes.

10-K filing | 0.9M shares outstanding

8-K filing: Quoin Pharmaceuticals Ltd. completed a public offering of approximately $6.5 million of securities, including ordinary shares represented by American Depositary Shares (ADSs), Series D warrants, Series E warrants, and pre-funded warrants. ($6.5M proceeds)

S-1/A filing: This is an S-1/A filing that describes the terms and conditions of pre-funded warrants and warrants to purchase common stock.

10-Q filing | 1.0M shares outstanding

8-K filing: Stock split 1-for-60,000 | Outstanding: 987,217 → 100,000,000

8-K filing: On October 26, 2023, Quoin's non-employee directors received an annual grant of an option to purchase 7,652 ADSs at an exercise price per ADS of $5.75, vesting over a four-year period.

10-Q filing | 1.0M shares outstanding

10-Q filing | 59233.0M shares outstanding

10-K filing | 24233.0M shares outstanding

8-K filing: Quoin Pharmaceuticals Ltd. closed a registered public offering on February 24, 2023, selling 4,950,000 ADSs at $1.00 per ADS and pre-funded warrants to purchase 2,050,000 ADSs at $0.9999 per pre-funded warrant, receiving gross proceeds of approximately $7 million before deducting fees and expenses, while also amending existing warrants with certain purchasers to reduce the exercise price to $1.10 and extend the term to February 24, 2028. ($7.0M proceeds)

S-1/A filing: This is an S-1/A filing that includes details on director and executive compensation, as well as the description of warrants being offered.

S-1 filing: This is an S-1 filing that describes the terms and conditions of Pre-Funded Warrants and Common Warrants being offered.

F-1 filing: This is an F-1 filing describing the terms and conditions of Pre-Funded Warrants and Common Warrants that are being offered.

RW filing: Quoin Pharmaceuticals Ltd. requests the withdrawal of its Registration Statement on Form F-3 filed on June 14, 2022, as the company has decided not to proceed with the proposed offering and sale of securities at this time.

F-3 filing: The filing is for a shelf registration to offer and sell up to $100,000,000 of ordinary shares represented by American Depositary Shares, subscription rights, debt securities, and units.

F-1 filing: This F-1 filing details the compensation structure for non-employee directors, including annual retainers, committee chairperson retainers, standing committee retainers, and equity awards. It also outlines the employment agreements for executive officers and itemizes the expenses related to the offering.

20-F filing | 3354.7M shares outstanding

20-F filing | 390.9M shares outstanding

20-F filing | 224.1M shares outstanding